Assuming multiple is required, the following results were found.

  • Multiple Sclerosis Market: Global Product Intelligence, Analysis, Opportunities and Forecast to 2025 - Press Release - Digital Journal

    by SBWire Pune, India -- (SBWIRE) -- 12/02/2019 -- Infinium Global Research has recently published a report on "Multiple Sclerosis Market(Treatment Modality - injectable Agents, and Oral Agents; Application - Hospital, and Research): Global Industry...

    https://mschristian.org/index.php/blog/multiple-sclerosis-market-global-product-intelligence-analysis-opportunities-and-forecast-to-2025-press-release-digital-journal
  • Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) | Small Molecules | News Channels - PipelineReview.com

    positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) DetailsHits: 158If approved, Mayzent® (siponimod) will be the first and only oral treatment specifically...

    https://mschristian.org/index.php/blog/novartis-receives-positive-chmp-opinion-for-mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis-spms-small-molecules-news-channels-pipelinereview-com
  • Global Primary Progressive Multiple Sclerosis Treatment Market 2019 – F. Hoffmann-La Roche Ltd., Genzyme Corporation, Glialogix, Inc. - Industry Report 24

    The Primary Progressive Multiple Sclerosis Treatment report delivers a comprehensive and systematic framework of the worldwide Primary Progressive Multiple Sclerosis Treatment Market at a global level that includes all the key aspects related to it....

    https://mschristian.org/index.php/blog/global-primary-progressive-multiple-sclerosis-treatment-market-2019-f-hoffmann-la-roche-ltd-genzyme-corporation-glialogix-inc-industry-report-24
  • Global Multiple Sclerosis Market by Types, Applications, Countries, Companies and Forecasts to 2024 covered in a Latest Research - Market Research Reporting

    Market share of global Multiple Sclerosis industry is dominate by companies like Abbvie, Acorda Therapeutics, Bayer HealthCare, Biogen, Genzyme (Sanofi), GlaxoSmithKline, Merck Serono, Novartis, Pfizer, Teva and others which are profiled in this report...

    https://mschristian.org/index.php/blog/global-multiple-sclerosis-market-by-types-applications-countries-companies-and-forecasts-to-2024-covered-in-a-latest-research-market-research-reporting
  • Global Multiple Sclerosis Drugs Production Market Share, Revenue, and Average Price by Manufacturers Shared in a Latest Research Report - Market Research Writeup

    Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and...

    https://mschristian.org/index.php/blog/global-multiple-sclerosis-drugs-production-market-share-revenue-and-average-price-by-manufacturers-shared-in-a-latest-research-report-market-research-writeup
  • Multiple sclerosis: Helping cells to help themselves

    Date:Source:Charité - Universitätsmedizin BerlinSummary:Diseases such as multiple sclerosis are characterized by damage to the 'myelin sheath', a protective covering wrapped around nerve cells akin to insulation around an electrical wire. Researchers...

    https://mschristian.org/index.php/blog/multiple-sclerosis-helping-cells-to-help-themselves
  • "Treating MS: A Simplified Strategy Boosts Patient and Provider Satisfaction"

    of neuroimmunology evolves at an unprecedented rate, keeping up with the latest advancements in diagnosis and treatment of multiple sclerosis (MS) proves challenging. Many neurologists—even those who spend most of their time in the MS space—are...

    https://mschristian.org/index.php/blog/treating-ms-a-simplified-strategy-boosts-patient-and-provider-satisfaction
  • Multiple Sclerosis Drugs Market 2019| Recent Trends, In-depth Analysis, Market Size Research Report Forecast up to 2026 | Research Industry US - News Obtain

    Global Multiple Sclerosis Drugs Market presents insights on the current and future industry trends, enabling the readers to identify the product and services, hence driving the revenue growth and profitability. The research report provides a detailed...

    https://mschristian.org/index.php/blog/multiple-sclerosis-drugs-market-2019-recent-trends-in-depth-analysis-market-size-research-report-forecast-up-to-2026-research-industry-us-news-obtain
  • Brain's lymphatic vessels as new avenue to treat multiple sclerosis

    Lymphatic vessels that clean the brain of harmful material play a crucial role in the development and progression of multiple sclerosis, new research from the University of Virginia School of Medicine suggests. The vessels appear to carry previously...

    https://mschristian.org/index.php/blog/brain-s-lymphatic-vessels-as-new-avenue-to-treat-multiple-sclerosis
  • Link between gut flora and multiple sclerosis discovered

    Date:Source:University of ZurichSummary:In multiple sclerosis, a defective response of the body's own immune system leads to brain tissue damage. Gastrointestinal microbiota could play a far greater role in the pathogenesis of the disease than...

    https://mschristian.org/index.php/blog/link-between-gut-flora-and-multiple-sclerosis-discovered
  • First clues to the causes of multiple sclerosis

    Multiple sclerosis, which affects 1 in 1,000 people, is frequently characterised by relapses associated with variable functional impairments including among others vision problems, impairment of locomotor functions or difficulties with speech. There is...

    https://mschristian.org/index.php/blog/first-clues-to-the-causes-of-multiple-sclerosis
  • What to know about secondary progressive multiple sclerosis (SPMS)

    Table of contents Secondary progressive multiple sclerosis is a later stage of multiple sclerosis. Instead of having symptom relapses and remissions, a person's symptoms steadily get worse over time. Most people, but not everyone, with...

    https://mschristian.org/index.php/blog/what-to-know-about-secondary-progressive-multiple-sclerosis-spms-1
  • Aubagio (teriflunomide)

    doctor right away. What is Aubagio? Aubagio is a brand-name prescription medication. It's used to treat relapsing forms of multiple sclerosis (MS) in adults. MS is an illness in which your immune system attacks your central nervous system. Aubagio...

    https://mschristian.org/index.php/blog/aubagio-teriflunomide
  • Chemical compound produces beneficial inflammation, remyelination that could help treat multiple sclerosis

    Drugs available to treat multiple sclerosis, a leading cause of neurological disability affecting roughly 2.3 million people worldwide, alter the body's immune system to reduce disease symptoms and disability. They do not induce, however, repair of...

    https://mschristian.org/index.php/blog/chemical-compound-produces-beneficial-inflammation-remyelination-that-could-help-treat-multiple-sclerosis
  • The MS Coalition invites you to join us for the 2019 Multiple Sclerosis Summit on Saturday, November 9, 2019 at the Westin Lombard, Illinois

    2019 Multiple Sclerosis Summit Saturday, November 9, 2019 – Lombard, Illinois The MS Coalition invites you to join us for the 2019 Multiple Sclerosis Summit on Saturday, November 9, 2019 at the Westin Lombard located at 70 Yorktown Center in Lombard,...

    https://mschristian.org/index.php/blog/the-ms-coalition-invites-you-to-join-us-for-the-2019-multiple-sclerosis-summit-on-saturday-november-9-2019-at-the-westin-lombard-illinois
  • B cells among factors leading to brain lesions in multiple sclerosis

    Date:Source:University of ZurichSummary:A team of researchers has shown that in multiple sclerosis, it is not only specific T cells that cause inflammation and lesions in the brain. B cells, a different type of immune cell, also play a role. These...

    https://mschristian.org/index.php/blog/b-cells-among-factors-leading-to-brain-lesions-in-multiple-sclerosis
  • Multiple sclerosis: Perilous ruptures

    Date:Source:Ludwig-Maximilians-Universität MünchenSummary:The permanent neurological deficits of multiple sclerosis patients largely depend on the extent of degeneration of long nerve fibers. The latter is initiated by ruptures in the cell membrane and...

    https://mschristian.org/index.php/blog/multiple-sclerosis-perilous-ruptures
  • Tecfidera (dimethyl fumarate)

    is Tecfidera? Tecfidera (dimethyl fumarate) is a brand-name prescription medication. It's used to treat relapsing forms of multiple sclerosis (MS). Tecfidera is classified as a disease-modifying therapy for MS. It reduces the risk of MS relapse by up to...

    https://mschristian.org/index.php/blog/tecfidera-dimethyl-fumarate
  • Fooling nerve cells into acting normal

    Discovery could inform future studies related to spinal cord injuries, multiple sclerosis and epilepsy Date:Source:University of Missouri-ColumbiaSummary:Scientists have discovered that a neuron's own electrical signal, or voltage, can indicate whether...

    https://mschristian.org/index.php/blog/fooling-nerve-cells-into-acting-normal
  • Conceptual framework to study role of exercise in multiple sclerosis

    a conceptual framework for examining the relationship between exercise and adaptive neuroplasticity in the population with multiple sclerosis (MS). FULL STORY Researchers have proposed a conceptual framework for examining the relationship between...

    https://mschristian.org/index.php/blog/conceptual-framework-to-study-role-of-exercise-in-multiple-sclerosis

Results 1 - 20 of 254
 
 

Follow Us on Twitter

Follow Us On Twitter - Image